Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis

Future Oncology, Ahead of Print.

Source: Future Oncology - July 27, 2023 Category: Cancer & Oncology Authors: Tianqi Zhang Danni Xie Xinhui Ye Yinuo Wang Xue Sun Qingchun Zhao Tianshu Ren Source Type: research